Search

Your search keyword '"Ehrlich, Peter F."' showing total 580 results
Start Over Author "Ehrlich, Peter F."
580 results on '"Ehrlich, Peter F."'

1. Central Venous Catheter Consideration in Pediatric Oncology: A Systematic Review and Meta-analysis From the American Pediatric Surgical Association Cancer Committee

Author

Christison-Lagay, Emily R., Brown, Erin G., Bruny, Jennifer, Funaro, Melissa, Glick, Richard D., Dasgupta, Roshni, Grant, Christa N., Engwall-Gill, Abigail J., Lautz, Timothy B., Rothstein, David, Walther, Ashley, Ehrlich, Peter F., Aldrink, Jennifer H., Rodeberg, David, and Baertschiger, Reto M.

Published
2024
Full Text
View/download PDF

3. Diagnostic Performance of Magnetic Resonance Imaging for Pediatric Ovarian Neoplasms: A Multi-Institutional Review

Author

Bergus, Katherine C., Knaus, Maria E., Onwuka, Amanda J., Afrazi, Amin, Breech, Lesley, Corkum, Kristine S., Dillon, Patrick A., Ehrlich, Peter F., Fallat, Mary E., Fraser, Jason D., Gadepalli, Samir K., Grabowski, Julia E., Hertweck, S. Paige, Kabre, Rashmi, Lal, Dave R., Landman, Matthew P., Leys, Charles M., Mak, Grace Z., Markel, Troy A., Merchant, Naila, Overman, R. Elliott, Rademacher, Brooks L., Raiji, Manish T., Rymeski, Beth, Sato, Thomas T., Wright, Tiffany, Aldrink, Jennifer H., Hewitt, Geri D., Minneci, Peter C., and Deans, Katherine J.

Published
2024
Full Text
View/download PDF

4. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children’s Oncology Group AREN18B5-Q

Author

Murphy, Andrew J., Cheng, Changde, Williams, Justin, Shaw, Timothy I., Pinto, Emilia M., Dieseldorff-Jones, Karissa, Brzezinski, Jack, Renfro, Lindsay A., Tornwall, Brett, Huff, Vicki, Hong, Andrew L., Mullen, Elizabeth A., Crompton, Brian, Dome, Jeffrey S., Fernandez, Conrad V., Geller, James I., Ehrlich, Peter F., Mulder, Heather, Oak, Ninad, Maciezsek, Jamie, Jablonowski, Carolyn M., Fleming, Andrew M., Pichavaram, Prahalathan, Morton, Christopher L., Easton, John, Nichols, Kim E., Clay, Michael R., Santiago, Teresa, Zhang, Jinghui, Yang, Jun, Zambetti, Gerard P., Wang, Zhaoming, Davidoff, Andrew M., and Chen, Xiang

Published
2023
Full Text
View/download PDF

6. Pediatric Surgery Firearm Injury Collaborative Symposium

Author

Henry, Marion C., Ehrlich, Peter F., Flynn O'Brien, Katherine T., Griggs, Cornelia, Hartman, Heather A., Kotagal, Meera, Masiakos, Peter, Naik-Mathuri, Bindi, Sathya, Chethan, Stevens, Jenny, Thomas, Arielle, Trinidad, Stephen, Williams, Regan, and Campbell, Brendan T.

Published
2024
Full Text
View/download PDF

7. Comparison of Outcomes Between Surveillance Ultrasound and Completion Lymph Node Dissection in Children and Adolescents With Sentinel Lymph Node-Positive Cutaneous Melanoma

Author

Scoville, Steven D., Stanek, Joseph R., Rinehardt, Hannah, Sutthatarn, Pattamon, Abdelhafeez, Abdelhafeez H., Talbot, Lindsay J., Malek, Marcus, Leraas, Harold J., Tracy, Elisabeth T., Chen, Stephanie Y., Kim, Eugene S., Lotakis, Dimitra M., Ehrlich, Peter F., Favela, Juan G., Le, Hau D., Davidson, Jacob, Wilson, Claire A., Seemann, Natashia M., Osman, Yasmin, Piche, Nelson, Hoang, Victoria, Petroze, Robin T., Polites, Stephanie F., McKay, Katlyn G., Correa, Hernan, Lovvorn, Harold N., III, Lee, Yu M., Balagani, Akshitha, Dasgupta, Rohni, and Aldrink, Jennifer H.

Published
2024
Full Text
View/download PDF

8. Management and Outcomes of Wilms Tumor With Suprarenal Intravascular Extension: A Pediatric Surgical Oncology Research Collaborative Study

Author

Naik-Mathuria, Bindi, Utria, Alan F., Ehrlich, Peter F., Aldrink, Jennifer H., Murphy, Andrew J., Lautz, Timothy, Dasgupta, Roshni, Short, Scott S., Lovvorn, Harold N., III, Kim, Eugene S., Newman, Erica, Lal, Dave R., Rich, Barrie S., Piché, Nelson, Kastenberg, Zachary J., Malek, Marcus M., Glick, Richard D., Petroze, Robin T., Polites, Stephanie F., Whitlock, Richard, Alore, Elizabeth, Sutthatarn, Pattamon, Chen, Stephanie Y., Wong-Michalak, Shannon, Romao, Rodrigo LP, Al-Hadidi, Ameer, Rubalcava, Nathan S., Marquart, John P., Gainer, Hailey, Johnson, Mike, Boehmer, Chloe, Rinehardt, Hannah, Seemann, Natashia M., Davidson, Jacob, Polcz, Valerie, Lund, Sarah B., McKay, Katlyn G., Correa, Hernan, and Rothstein, David H.

Published
2024
Full Text
View/download PDF

13. Use and Accuracy of Intraoperative Frozen Section Analysis for Ovarian Masses in Children and Adolescents

Author

Gil, Lindsay A., Lutz, Carley M., Dillon, Patrick A., Downard, Cynthia D., Ehrlich, Peter F., Fallat, Mary E., Fraser, Jason D., Grabowski, Julia E., Helmrath, Michael A., Hertweck, S. Paige, Hirschl, Ronald B., Kabre, Rashmi, Lal, Dave R., Landman, Matthew P., Lawrence, Amy E., Leys, Charles M., Mak, Grace Z., Markel, Troy A., Raiji, Manish T., Rymeski, Beth, Saito, Jacqueline M., Sato, Thomas T., St. Peter, Shawn D., Stafford, Linda M. Cherney, Deans, Katherine J., Minneci, Peter C., Hewitt, Geri D., and Aldrink, Jennifer H.

Published
2023
Full Text
View/download PDF

14. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

Author

Dix, David B, Fernandez, Conrad V, Chi, Yueh-Yun, Mullen, Elizabeth A, Geller, James I, Gratias, Eric J, Khanna, Geetika, Kalapurakal, John A, Perlman, Elizabeth J, Seibel, Nita L, Ehrlich, Peter F, Malogolowkin, Marcio, Anderson, James, Gastier-Foster, Julie, Shamberger, Robert C, Kim, Yeonil, Grundy, Paul E, and Dome, Jeffrey S

Subjects
Clinical Research, Cancer, Pediatric, Pediatric Cancer, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Biomarkers, Tumor, Chromosomes, Human, Pair 1, Female, Humans, Kidney Neoplasms, Loss of Heterozygosity, Male, Progression-Free Survival, Prospective Studies, Retrospective Studies, Wilms Tumor, Young Adult, AREN0532 and AREN0533 study committees, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeIn National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p/16q) was associated with adverse outcomes in patients with favorable histology Wilms tumor. The AREN0533/AREN0532 studies assessed whether augmenting therapy improved event-free survival (EFS) for these patients. Patients with stage I/II disease received regimen DD4A (vincristine, dactinomycin and doxorubicin) but no radiation therapy. Patients with stage III/IV disease received regimen M (vincristine, dactinomycin, and doxorubicin alternating with cyclophosphamide and etoposide) and radiation therapy.MethodsPatients were enrolled through the AREN03B2 Biology study between October 2006 and October 2013; all underwent central review of pathology, surgical reports, and imaging. Tumors were evaluated for LOH1p/16q by microsatellite testing. EFS and overall survival were compared using the log-rank test between NWTS-5 and current studies.ResultsLOH1p/16q was detected in 49 of 1,147 evaluable patients with stage I/II disease (4.27%) enrolled in AREN03B2; 32 enrolled in AREN0532. LOH1p/16q was detected in 82 of 1,364 evaluable patients with stage III/IV disease (6.01%) in AREN03B2; 51 enrolled in AREN0533. Median follow-up for 83 eligible patients enrolled in AREN0532/0533 was 5.73 years (range, 2.84 to 9.63 years). The 4-year EFS for patients with stage I/II and stage III/IV disease with LOH1p/16 was 87.3% (95% CI, 75.1% to 99.5%) and 90.2% (95% CI, 81.8% to 98.6%), respectively. These results are improved compared with the NWTS-5 updated 4-year EFS of 68.8% for patients with stage I/II disease (P = .042), and 61.3% for patients with stage III/IV disease (P = .001), with trends toward improved 4-year overall survival. The most common grade 3 or higher nonhematologic toxicities with regimen M were febrile neutropenia (39.2%) and infections (21.6%).ConclusionAugmentation of therapy improved EFS for patients with favorable histology Wilms tumor and LOH1p/16q compared with the historical NWTS-5 comparison group, with an expected toxicity profile.

Published
2019

17. Current surgical approaches to pediatric renal tumors

Author

Glick, Richard D., primary, Romao, Rodrigo L. P., additional, Pachl, Max, additional, Kotagal, Meera, additional, Buchanan, Amanda F., additional, Murphy, Andrew J., additional, Tracy, Elisabeth T., additional, Pio, Luca, additional, Cost, Nicholas G., additional, Godzinski, Jan, additional, and Ehrlich, Peter F., additional

Published
2024
Full Text
View/download PDF

18. Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children’s Oncology Group Study AREN0534

Author

Ehrlich, Peter F., Tornwall, Brett, Chintagumpala, Murali M., Chi, Yueh-Yun, Hoffer, Fredric A., Perlman, Elizabeth J., Kalapurakal, John A., Warwick, Anne, Shamberger, Robert C., Khanna, Geetika, Hamilton, Thomas E., Gow, Kenneth W., Paulino, Arnold C., Gratias, Eric J., Mullen, Elizabeth A., Geller, James I., Fernandez, Conrad V., and Dome, Jeffrey S.

Published
2022
Full Text
View/download PDF

19. Pediatric surgery milestones 2.0: A primer

Author

Alaish, Samuel M., Arca, Marjorie J., Bucher, Brian T., Cooney, Cathi, Diesen, Diana L., Ehrlich, Peter F., Gaines, Barbara A., Griggs, Cornelia L., Javid, Patrick J., Krishnaswami, Sanjay, Middlesworth, William, Wong, Cynthia L., and Edgar, Laura

Published
2022
Full Text
View/download PDF

20. Multi-Institutional Review of the Preoperative Diagnostic Accuracy for Pediatric Ovarian Mature Cystic Teratomas

Author

Knaus, Maria E., Onwuka, Amanda J., Afrazi, Amin, Breech, Lesley, Corkum, Kristine S., Dillon, Patrick A., Ehrlich, Peter F., Fallat, Mary E., Fraser, Jason D., Gadepalli, Samir K., Grabowski, Julia E., Hertweck, S. Paige, Kabre, Rashmi, Lal, Dave R., Landman, Matthew P., Lawrence, Amy E., Leys, Charles M., Mak, Grace Z., Markel, Troy A., Merchan, Naila, Overman, R. Elliott, Rademacher, Brooks L., Raiji, Manish T., Rymeski, Beth, Sato, Thomas T., Scannel, Madeline, Schikler, Allegra G., Sujka, Joseph A., Wright, Tiffany, Aldrink, Jennifer H., Hewitt, Geri D., Minneci, Peter C., and Deans, Katherine J.

Published
2022
Full Text
View/download PDF

21. Interhospital variability in localization techniques for small pulmonary nodules in children: A pediatric surgical oncology research collaborative study

Author

Morgan, Katrina M., Anderson, K. Tinsley, Johnston, Michael E., Dasgupta, Roshni, Crowley, John J., Fahy, Aodhnait S., Lapidus-Krol, Eveline, Baertschiger, Reto M., Lautz, Timothy B., Many, Benjamin T., Marquart, John P., Gainer, Haley, Lal, Dave R., Rich, Barrie S., Glick, Richard D., MacArthur, Taleen A., Polites, Stephanie F., Kastenberg, Zachary J., Short, Scott S., Meyers, Rebecka L., Talbot, Lindsay, Abdelhafeez, Abdelhafeez, Prajapati, Hasmukh, Davidoff, Andrew M., Rubaclava, Nathan, Newman, Erika, Ehrlich, Peter F., Rothstein, David H., Roach, Jonathan P., Ladd, Patricia, Janek, Kevin C., Le, Hau D., Leraas, Harold J., Tracy, Elisabeth T., Bisset, Logan, Mora, Maria C., Warren, Patrick, Aldrink, Jennifer H., and Malek, Marcus M.

Published
2022
Full Text
View/download PDF

22. Laparoscopy versus laparotomy for pediatric ovarian dermoids

Author

Knaus, Maria E., Onwuka, Amanda J., Afrazi, Amin, Breech, Lesley, Corkum, Kristine S., Dillon, Patrick A., Ehrlich, Peter F., Fallat, Mary E., Fraser, Jason D., Gadepalli, Samir K., Grabowski, Julia E., Hertweck, S. Paige, Kabre, Rashmi, Lal, Dave R., Landman, Matthew P., Lawrence, Amy E., Leys, Charles M., Mak, Grace Z., Markel, Troy A., Merchant, Naila, Elliott Overman, R., Rademacher, Brooks L., Raiji, Manish T., Rymeski, Beth, Sato, Thomas T., Scannell, Madeline, Schikler, Allegra G., Sujka, Joseph A., Wright, Tiffany, Aldrink, Jennifer H., Hewitt, Geri D., Minneci, Peter C., and Deans, Katherine J.

Published
2022
Full Text
View/download PDF

23. Update on pediatric testicular germ cell tumors

Author

Aldrink, Jennifer H., Glick, Richard D., Baertschiger, Reto M., Kulaylat, Afif N., Lautz, Timothy B., Christison-Lagay, Emily, Grant, Christa N., Tracy, Elisabeth, Dasgupta, Roshni, Brown, Erin G., Mattei, Peter, Rothstein, David H., Rodeberg, David A., and Ehrlich, Peter F.

Published
2022
Full Text
View/download PDF

26. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2.

Author

Benedetti, Daniel J., Renfro, Lindsay A., Tfirn, Ian, Daw, Najat C., Kalapurakal, John A., Ehrlich, Peter F., Khanna, Geetika, Perlman, Elizabeth, Warwick, Anne, Gow, Kenneth W., Paulino, Arnold C., Seibel, Nita L., Grundy, Paul, Fernandez, Conrad V., Geller, James I., Mullen, Elizabeth A., and Dome, Jeffrey S.

Subjects
SARCOMA, CENTRAL nervous system, NEPHROBLASTOMA, KIDNEYS, DISEASE progression
Abstract

Background: On the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5‐year event‐free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children's Oncology Group study AREN0321 of risk‐adapted therapy, RT was omitted for stage I disease if lymph nodes were sampled, and carboplatin was added for stage IV disease (regimen UH‐1). Patients who had stage II/III disease received regimen I with RT. Methods: Four‐year EFS was analyzed for patients enrolled on AREN0321 and on those enrolled on AREN03B2 who received AREN0321 stage‐appropriate chemotherapy. Results: Eighty‐two patients with CCSK enrolled on AREN0321, 50 enrolled on AREN03B2 only. The 4‐year EFS rate was 82.7% (95% confidence interval [CI], 74.8%–91.4%) for AREN0321 and 89.6% (95% CI, 81.3%–98.7%) for AREN03B2 only (p =.28). When combining studies, the 4‐year EFS rates for patients who had stage I (n = 10), II (n = 47), III (n = 65), and IV (n = 10) disease were 90% (95% CI, 73.2%–100.0%), 93.4% (95% CI, 86.4%–100.0%), 82.8% (95% CI, 74.1%–92.6%), and 58.3% (95% CI, 34%–100.0%), respectively. There were no local recurrences among seven patients with stage I disease who were treated without RT. One stage I recurrence occurred in the brain, which was the most common site of relapse overall. Among patients with local stage III tumors, neither initial procedure type, margin status, nor lymph node involvement were prognostic. Conclusions: Patients with stage I CCSK had excellent outcomes without local recurrences when treated without RT. Patients with stage IV disease appeared to benefit from a carboplatin‐containing regimen, although their outcomes remained unsatisfactory. Further research is needed to improve outcomes for patients with advanced‐stage disease (ClinicalTrials.gov identifiers NCT00335556 and NCT00898365). The results of this study indicate that treatment of clear cell sarcoma of the kidney can be risk‐adapted based on disease stage, radiotherapy should be omitted for patients with stage I disease if lymph nodes are sampled, and patients with stage IV disease appear to benefit from a carboplatin‐containing regimen. With treatment according to the Children's Oncology Group AREN0321 study, most relapses occurred within 3 years, and the most common sites of recurrence were in the central nervous system. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

Author

Dix, David B, Seibel, Nita L, Chi, Yueh-Yun, Khanna, Geetika, Gratias, Eric, Anderson, James R, Mullen, Elizabeth A, Geller, James I, Kalapurakal, John A, Paulino, Arnold C, Perlman, Elizabeth J, Ehrlich, Peter F, Malogolowkin, Marcio, Gastier-Foster, Julie M, Wagner, Elizabeth, Grundy, Paul E, Fernandez, Conrad V, and Dome, Jeffrey S

Subjects
Rare Diseases, Cancer, Lung, Lung Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Child, Child, Preschool, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Female, Humans, Lung Neoplasms, Male, Neoplasm Staging, Risk Factors, Survival Rate, Treatment Outcome, Vincristine, Wilms Tumor, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose The National Wilms Tumor Study (NWTS) treatment of favorable histology Wilms tumor with lung metastases was vincristine/dactinomycin/doxorubicin (DD4A) and lung radiation therapy (RT). The AREN0533 study applied a new risk stratification and treatment strategy to improve event-free survival (EFS) while reducing exposure to lung RT. Methods Patients with favorable histology Wilms tumor and isolated lung metastases showing complete lung nodule response (CR) after 6 weeks of DD4A continued receiving chemotherapy without lung RT. Patients with incomplete response (IR) or loss of heterozygosity at chromosomes 1p/16q received lung RT and four cycles of cyclophosphamide/etoposide in addition to DD4A drugs (Regimen M). AREN0533 was designed to preserve a 4-year EFS of 85% for lung nodule CR and improve 4-year EFS from 75% to 85% for lung nodule IR. Results Among 292 assessable patients, 133 had CR and 159 had IR. For patients with CR, 4-year EFS and overall survival (OS) estimates were 79.5% (95% CI, 71.2% to 87.8%) and 96.1% (95% CI, 92.1% to 100%), respectively. Expected versus observed event rates were 15% and 20.2% ( P = .052), respectively. For patients with IR, 4-year EFS and OS estimates were 88.5% (95% CI, 81.8% to 95.3%) and 95.4% (95% CI, 90.9% to 99.8%), respectively. Expected versus observed event rates were 25% and 12.2% ( P < .001), respectively. Overall, 4-year EFS and OS were 85.4% (95% CI, 80.5% to 90.2%) and 95.6% (95% CI, 92.8% to 98.4%) compared with 72.5% (95% CI, 66.9% to 78.1%; P < .001) and 84.0% (95% CI, 79.4% to 88.6%; P < .001), respectively, in the predecessor NWTS-5 study. Conclusion Excellent OS was achieved after omission of primary lung RT in patients with lung nodule CR, although there were more events than expected. EFS was significantly improved, with excellent OS, in patients with lung nodule IR using four cycles of cyclophosphamide/etoposide in addition to DD4A drugs. The overall AREN0533 treatment strategy yielded EFS and OS estimates that were superior to previous studies.

Published
2018

28. Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children’s Oncology Group Study, AREN03B2

Author

Lovvorn, Harold N, primary, Renfro, Lindsay A, additional, Benedetti, Daniel J, additional, Kotagal, Meera, additional, Phelps, Hannah M, additional, Ehrlich, Peter F, additional, Lo, Andrea C, additional, Sandberg, Jesse K, additional, Treece, Amanda L, additional, Gow, Kenneth W, additional, Glick, Richard D, additional, Davidoff, Andrew M, additional, Cost, Nicholas G, additional, Dix, David B, additional, Fernandez, Conrad V, additional, Dome, Jeffrey S, additional, Geller, James I, additional, and Mullen, Elizabeth A, additional

Published
2024
Full Text
View/download PDF

34. Pediatric Colorectal Disorders

Author

Teitelbaum, Daniel H., Ehrlich, Peter F., Steele, Scott R., editor, Hull, Tracy L., editor, Hyman, Neil, editor, Maykel, Justin A., editor, Read, Thomas E., editor, and Whitlow, Charles B., editor

Published
2019
Full Text
View/download PDF

36. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5

Author

Benedetti, Daniel J., primary, Varela, Carly R., additional, Renfro, Lindsay A., additional, Tornwall, Brett, additional, Dix, David B., additional, Ehrlich, Peter F., additional, Glick, Richard D., additional, Kalapurakal, John, additional, Perlman, Elizabeth, additional, Gratias, Eric, additional, Seibel, Nita L., additional, Geller, James I., additional, Khanna, Geetika, additional, Malogolowkin, Marcio, additional, Grundy, Paul, additional, Fernandez, Conrad V., additional, Dome, Jeffrey S., additional, and Mullen, Elizabeth A., additional

Published
2023
Full Text
View/download PDF

37. Diagnostic Performance of Magnetic Resonance Imaging for Pediatric Ovarian Neoplasms: A Multi-Institutional Review

Author

Bergus, Katherine C., primary, Knaus, Maria E., additional, Onwuka, Amanda J., additional, Afrazi, Amin, additional, Breech, Lesley, additional, Corkum, Kristine S., additional, Dillon, Patrick A., additional, Ehrlich, Peter F., additional, Fallat, Mary E., additional, Fraser, Jason D., additional, Gadepalli, Samir K., additional, Grabowski, Julia E., additional, Hertweck, S. Paige, additional, Kabre, Rashmi, additional, Lal, Dave R., additional, Landman, Matthew P., additional, Leys, Charles M., additional, Mak, Grace Z., additional, Markel, Troy A., additional, Merchant, Naila, additional, Overman, R. Elliott, additional, Rademacher, Brooks L., additional, Raiji, Manish T., additional, Rymeski, Beth, additional, Sato, Thomas T., additional, Wright, Tiffany, additional, Aldrink, Jennifer H., additional, Hewitt, Geri D., additional, Minneci, Peter C., additional, and Deans, Katherine J., additional

Published
2023
Full Text
View/download PDF

38. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532

Author

Evageliou, Nicholas, primary, Renfro, Lindsay A., additional, Geller, James, additional, Perlman, Elizabeth, additional, Kalapurakal, John, additional, Paulino, Arnold, additional, Dix, David, additional, Eklund, Meryle J., additional, Murphy, Andrew J., additional, Romao, Rodrigo L. P., additional, Ehrlich, Peter F., additional, Varela, Carly R., additional, Vallance, Kelly, additional, Fernandez, Conrad V., additional, Dome, Jeffrey S., additional, and Mullen, Elizabeth A., additional

Published
2023
Full Text
View/download PDF

39. ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis—A Report from the Children’s Oncology Group Study AREN0534

Author

Ehrlich, Peter F., Tornwall, Brett, Chintagumpala, Murali M., Chi, Yueh-Yun, Hoffer, Fredric A., Perlman, Elizabeth J., Kalapurakal, John A., Warwick, Anne, Shamberger, Robert C., Khanna, Geetika, Hamilton, Thomas E., Gow, Kenneth W., Paulino, Arnold C., Gratias, Eric J., Mullen, Elizabeth A., Geller, James I., Fernandez, Conrad V., and Dome, Jeffrey S.

Published
2022
Full Text
View/download PDF

41. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5.

Author

Benedetti, Daniel J., Varela, Carly R., Renfro, Lindsay A., Tornwall, Brett, Dix, David B., Ehrlich, Peter F., Glick, Richard D., Kalapurakal, John, Perlman, Elizabeth, Gratias, Eric, Seibel, Nita L., Geller, James I., Khanna, Geetika, Malogolowkin, Marcio, Grundy, Paul, Fernandez, Conrad V., Dome, Jeffrey S., and Mullen, Elizabeth A.

Subjects
NEPHROBLASTOMA, METASTASIS, PATIENT experience, PROGNOSIS, PATIENTS' attitudes
Abstract

Background: Patients with stage IV favorable histology Wilms tumor (FHWT) with extrapulmonary metastases (EPM) constitute a small subset of patients with FHWT. Because of their rarity and heterogeneity, optimal FHWT treatment is not well understood. Children's Oncology Group protocol AREN0533 assigned patients with FHWT and EPM to intensified chemotherapy, regimen M, after initial DD‐4A chemotherapy. To improve understanding of prognostic factors and best therapies, experiences of patients with EPM on AREN0533, as well as on protocols AREN03B2 and NWTS‐5, were reviewed. Methods: Combined outcomes for patients with EPM from NWTS‐5, AREN0533, and AREN03B2 were determined. Those treated on AREN0533 were compared with those treated on NWTS‐5. Prognostic factors were explored in the pooled cohort. Results: Forty‐seven patients with FHWT with EPM enrolled on AREN0533, 37 enrolled on NWTS‐5, and 64 were followed only on AREN03B2. The pooled cohort of all 148 patients demonstrated a 4‐year event‐free survival (EFS) of 77.3% (95% CI, 70.8–84.4) and 4‐year overall survival of 88.9% (95% CI, 83.9–94.2). Four‐year EFS of patients with EPM treated on AREN0533 was 76.0% (95% CI, 64.6–89.4) vs 64.9% (95% CI, 51.7–82.2) on NWTS‐5; hazard ratio, 0.64, p =.26; no difference in overall survival was observed. Increasing linear age and slow incomplete lung response were associated with worse EFS in a pooled cohort. Conclusions: Outcomes for patients with EPM are among the lowest for children with FHWT. Further trials with standardized surgical and radiation treatment to metastatic sites, and prospectively collected biologic and treatment details are needed. Clinical trial registration: Clinical Trials.gov identifiers: NCT00379340, NCT00898365, and NCT00002611. Pooled outcomes across three studies of patients with favorable histology Wilms tumor and extrapulmonary metastases revealed 4‐year event‐free survival of 77.3% and overall survival of 88.9%, with no statistical differences seen between patients on AREN0533 compared with those on NWTS‐5. Missing details on local management of metastatic sites informs a critical need for better data capture in future studies to optimize local control strategies and chemotherapy regimens for this higher‐risk favorable histology Wilms tumor patient group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.

Author

Evageliou, Nicholas, Renfro, Lindsay A., Geller, James, Perlman, Elizabeth, Kalapurakal, John, Paulino, Arnold, Dix, David, Eklund, Meryle J., Murphy, Andrew J., Romao, Rodrigo L. P., Ehrlich, Peter F., Varela, Carly R., Vallance, Kelly, Fernandez, Conrad V., Dome, Jeffrey S., and Mullen, Elizabeth A.

Subjects
NEPHROBLASTOMA, LYMPH nodes, HETEROZYGOSITY, HISTOLOGY, ONCOLOGY
Abstract

Introduction: The prognostic impact of positive lymph nodes (LN+) and/or singular loss of heterozygosity (LOH) of 1p or 16q were assessed in children with stage III favorable histology Wilms tumor (FHWT) enrolled on AREN0532 or AREN03B2 alone. Patients and Methods: A total of 635 stage III FHWT vincristine/dactinomycin/doxorubicin (DD4A)–treated patients met inclusion criteria. Event‐free survival (EFS) and overall survival are reported overall and by LN sampling, LN status, LOH 1p, LOH 16q, and a combination of LN status and singular LOH. Patients with unknown or positive combined LOH of 1p and 16q status and AREN03B2‐only patients with unknown outcomes or treatment other than DD4A were excluded. Results: EFS did not differ by study, supporting pooling. Lack of LN sampling (hazard ratio [HR], 2.12; p =.0037), LN positivity (HR, 2.78; p =.0002), LOH 1p (HR, 2.18; p =.0067), and LOH 16q (HR, 1.72; p =.042) were associated with worse EFS. Compared with patients with both LN– and LOH–, those with negative nodes but positive LOH 1p or 16q and those with LN+ but LOH– for 1p or 16q had significantly worse EFS (HR, 3.05 and 3.57, respectively). Patients positive for both LN and LOH had the worst EFS (HR, 6.33; overall group factor, p <.0001). Conclusion: Findings confirm LN+ status as an adverse prognostic factor amplified by presence of singular LOH 1p or 16q, supporting study of intensified therapy for patients with LN+ in combination with singular LOH in a prospective clinical trial. Stage III patients with favorable histology Wilms tumor and a combination of loss of heterozygosity of 1p or 16q and lymph node involvement were examined in an expanded Children's Oncology Group cohort. The combination of loss of heterozygosity status with lymph node status correlated with inferior outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. A Holistic Approach to Childhood Firearm Injuries.

Author

Pulcini, Christian D., Hoffmann, Jennifer A., Alpern, Elizabeth R., Chaudhary, Sofia, Ehrlich, Peter F., Fein, Joel A., Fleegler, Eric W., Goyal, Monika K., Hall, Matt, Jeffries, Kristyn N., Myers, Rachel, Sheehan, Karen M., Zamani, Mark, Zima, Bonnie T., and Hargarten, Stephen

Published
2024
Full Text
View/download PDF

45. Pediatric Surgery Firearm Injury Collaborative Symposium

Author

Henry, Marion C., primary, Ehrlich, Peter F., additional, Flynn O’Brien, Katherine T., additional, Griggs, Cornelia, additional, Hartman, Heather A., additional, Kotagal, Meera, additional, Masiakos, Peter, additional, Naik-Mathuri, Bindi, additional, Sathya, Chethan, additional, Stevens, Jenny, additional, Thomas, Arielle, additional, Trinidad, Stephen, additional, Williams, Regan, additional, and Campbell, Brendan T., additional

Published
2023
Full Text
View/download PDF

46. Comparison of Outcomes between Surveillance Ultrasound and Completion Lymph Node Dissection in Children and Adolescents with Sentinel Lymph Node Positive Cutaneous Melanoma

Author

Scoville, Steven D., primary, Stanek, Joseph R., additional, Rinehardt, Hannah, additional, Sutthatarn, Pattamon, additional, Abdelhafeez, Abdelhafeez H., additional, Talbot, Lindsay J., additional, Malek, Marcus, additional, Leraas, Harold J., additional, Tracy, Elisabeth T., additional, Chen, Stephanie Y., additional, Kim, Eugene S., additional, Lotakis, Dimitra M., additional, Ehrlich, Peter F., additional, Favela, Juan G., additional, Le, Hau D., additional, Davidson, Jacob, additional, Wilson, Claire A., additional, Seemann, Natashia M., additional, Osman, Yasmin, additional, Piche, Nelson, additional, Hoang, Victoria, additional, Petroze, Robin T., additional, Polites, Stephanie F., additional, McKay, Katlyn G., additional, Correa, Hernan, additional, Lovvorn, Harold N., additional, Lee, Yu M., additional, Balagani, Akshitha, additional, Dasgupta, Roshni, additional, and Aldrink, Jennifer H., additional

Published
2023
Full Text
View/download PDF

47. Wilms Tumor

Author

Ehrlich, Peter F., Mattei, Peter, editor, Nichol, Peter F., editor, Rollins, II, Michael D., editor, and Muratore, Christopher S., editor

Published
2017
Full Text
View/download PDF

48. Timing of Mental Health Service Use After a Pediatric Firearm Injury

Author

Hoffmann, Jennifer A., primary, Pulcini, Christian D., additional, Hall, Matt, additional, De Souza, Heidi G., additional, Alpern, Elizabeth R., additional, Chaudhary, Sofia, additional, Ehrlich, Peter F., additional, Fein, Joel A., additional, Fleegler, Eric W., additional, Goyal, Monika K., additional, Hargarten, Stephen, additional, Jeffries, Kristyn N., additional, and Zima, Bonnie T., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results